Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1GSK3AGSK3BHRH1HRH2HTR7IDH1IDH2IMPA1IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL107371 | 0.98 | CA4 (0.70) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL5471630 | 0.98 | CA4 (0.76) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL1410612 | 0.96 | CA4 (0.67) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL18263181 | 0.95 | CA4 (0.73) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL9319655 | 0.95 | CA4 (0.73) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL475574 | 0.95 | CA4 (0.73) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL1301477 | 0.95 | CA4 (0.73) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL21569387 | 0.95 | CA4 (0.73) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL21569398 | 0.95 | CA4 (0.73) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL2227446 | 0.95 | CA4 (0.73) | CA4ALDH1A1HMGCRCHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124418-B2 | Activated carbons with high surface areas and methods of making same | ADVEN INDUSTRIES, INC. (CA) | 2021-09-21 | — | — | US | claimed |
| CN-110534730-A | The preparation method of lithium titanate material | GOLINK TECH HUZHOU CO LTD | 2019-12-03 | — | — | CN | claimed |
| US-20190202702-A1 | Activated Carbons with High Surface Areas and Methods of Making Same | Adven Industries Inc. (CA) | 2019-07-04 | — | — | US | claimed |
| US-9962628-B2 | Use of citrate solution for affinity chromatographic purification of CRP using phosphocholine and derivatives thereof | PENTRACOR GMBH (DE) | 2018-05-08 | — | — | US | claimed |
| EP-3083665-B1 | USE OF A CITRATE SOLUTION FOR THE AFFINITY-CHROMATOGRAPHIC PURIFICATION OF CRP USING PHOSPHOCHOLIN AND ITS DERIVATIVES | PENTRACOR GMBH (DE) | 2018-01-10 | — | — | EP | claimed |
| US-20170319982-A1 | USE OF A CITRATE SOLUTION FOR AFFINITY CHROMATOGRAPHIC PURIFICATION OF CRP USING PHOSPHOCHOLINE AND DERIVATIVES THEREOF | PENTRACOR GMBH (DE) | 2017-11-09 | — | — | US | claimed |
| WO-2013028574-A2 | AQUEOUS LITHIUM AIR BATTERIES | POLYPLUS BATTERY COMPANY (US) | 2013-02-28 | — | — | WO | claimed |
| US-6855678-B2 | Medical residue treatment composition comprising a lithium salt | WHITELEY CORPORATION PTY LTD (AU) | 2005-02-15 | — | — | US | claimed |
| US-20030161758-A1 | Medical residue treatment composition | WHITELEY CORPORATION PTY LTD (AU) | 2003-08-28 | — | — | US | claimed |
| WO-2002007789-A1 | MEDICAL RESIDUE TREATMENT COMPOSITION | WHITELEY REGINALD KEITH (AU) | 2002-01-31 | — | — | WO | claimed |
| JP-6273938-A | — | — | None | — | — | JP | disclosed |
| US-20260118767-A1 | REVERSE PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2026-04-30 | — | — | US | disclosed |
| US-20260044081-A1 | COMPOSITION FOR FORMING SILICON-CONTAINING RESIST FILM AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2026-02-12 | — | — | US | disclosed |
| EP-4692941-A2 | COMPOSITION FOR FORMING SILICON-CONTAINING RESIST FILM AND PATTERNING PROCESS | Shin-Etsu Chemical Co., Ltd. (JP) | 2026-02-11 | — | — | EP | disclosed |
| EP-4621486-A2 | POLYVALENT AMMONIUM SALT COMPOUND, COMPOSITION FOR FORMING SILICON-CONTAINING RESIST UNDERLAYER FILM, AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-09-24 | — | — | EP | disclosed |
| US-6855678-B2 | Medical residue treatment composition comprising a lithium salt | WHITELEY CORPORATION PTY LTD (AU) | 2005-02-15 | — | — | US | disclosed |
| US-20030161758-A1 | Medical residue treatment composition | WHITELEY CORPORATION PTY LTD (AU) | 2003-08-28 | — | — | US | disclosed |
| WO-2002007789-A1 | MEDICAL RESIDUE TREATMENT COMPOSITION | WHITELEY REGINALD KEITH (AU) | 2002-01-31 | — | — | WO | disclosed |
| US-5453472-A | Antideposit agents for polymerization reactor walls | BASF AKTIENGESELLSCHAFT (DE) | 1995-09-26 | — | — | US | disclosed |
| JP-H06273938-A | METHOD FOR LOWERING PH OF WASTE DEVELOPER OF PHOTOSENSITIVE LITHOGRAPHIC PRINTING PLATE | FUJI PHOTO FILM CO LTD | 1994-09-30 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170319982-A1 | USE OF A CITRATE SOLUTION FOR AFFINITY CHROMATOGRAPHIC PURIFICATION OF CRP USING PHOSPHOCHOLINE AND DERIVATIVES THEREOF | PHOSPHO1, ACP1, ALB | CA4 353/4885ALDH1A1 4682/4885HMGCR 257/4885 |
| US-20260118767-A1 | REVERSE PATTERNING PROCESS | EFNA1, EPHA4, ETV6 | CA4 281/4885ALDH1A1 4452/4885HMGCR 3483/4885 |
| US-20260044081-A1 | COMPOSITION FOR FORMING SILICON-CONTAINING RESIST FILM AND PATTERNING PROCESS | SMC1A, SPOUT1, LBR | CA4 1681/4885ALDH1A1 1558/4885HMGCR 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.